Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
作者信息
Oren Ohad, Yang Eric H, Gluckman Ty J, Michos Erin D, Blumenthal Roger S, Gersh Bernard J
机构信息
Division of Hematology and Oncology, Mayo Clinic, Rochester, MN (O.O.).
Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.).
出版信息
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.
Abstract
摘要
相似文献
1
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.氯喹和羟氯喹在2019冠状病毒病中的应用及其心血管影响：理解安全性差异以改进临床试验的解读与设计
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.
2
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.用于治疗新冠肺炎的氯喹/羟氯喹引发室性心律失常的风险：是否应该使用该药？
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
3
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
4
Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?用于治疗新冠肺炎的氯喹或羟氯喹：心脏毒性是一个值得关注的问题吗？
J Am Heart Assoc. 2020 Jun 16;9(12):e016887. doi: 10.1161/JAHA.120.016887. Epub 2020 May 28.
5
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.新型冠状病毒肺炎与抗疟药物：弊大于利
Am J Crit Care. 2020 Nov 1;29(6):489-492. doi: 10.4037/ajcc2020694.
6
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).呼吁开展随机对照试验以测试氯喹和羟氯喹作为治疗新型冠状病毒病（COVID-19）药物的疗效
Am J Trop Med Hyg. 2020 May;102(5):932-933. doi: 10.4269/ajtmh.20-0230.
7
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
8
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.为何您的患者认为羟氯喹和氯喹对新冠病毒病有90%的疗效是极其危险的。
J Clin Pharmacol. 2020 Aug;60(8):949-953. doi: 10.1002/jcph.1687. Epub 2020 Jul 1.
9
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.氯喹和羟氯喹用于治疗新型冠状病毒肺炎的安全性考量
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
10
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.氯喹和羟氯喹在2019冠状病毒病中的应用：资源匮乏地区面临的挑战及谨慎使用的必要性
J Coll Physicians Surg Pak. 2020 Jun;30(6):78. doi: 10.29271/jcpsp.2020.Supp1.S78.
引用本文的文献
1
Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials.羟氯喹治疗非住院 COVID-19 成人患者：随机试验个体参与者数据的荟萃分析。
Clin Transl Sci. 2023 Mar;16(3):524-535. doi: 10.1111/cts.13468. Epub 2023 Jan 4.
2
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.羟氯喹的心脏毒性：COVID-19 大流行的教训。
Curr Heart Fail Rep. 2022 Dec;19(6):458-466. doi: 10.1007/s11897-022-00581-y. Epub 2022 Sep 27.
3
Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?长新冠和心脏：心脏线粒体是缺失的一环吗？
Antioxid Redox Signal. 2023 Mar;38(7-9):599-618. doi: 10.1089/ars.2022.0126. Epub 2022 Dec 28.
4
Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.COVID-19 感染患者羟氯喹治疗后 QTc 间期的变化：一项大型、回顾性、多中心队列研究。
BMJ Open. 2022 Feb 9;12(2):e051579. doi: 10.1136/bmjopen-2021-051579.
5
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.新冠病毒治疗药物的实验研究与临床评估的最新进展
Front Pharmacol. 2021 Nov 22;12:732403. doi: 10.3389/fphar.2021.732403. eCollection 2021.
6
Predictive Analysis of Factors Influencing Depression Status of Nurses in the COVID-19 Pandemic Intensive Care Unit.新型冠状病毒肺炎疫情重症监护病房护士抑郁状况影响因素的预测分析
Front Psychiatry. 2021 Nov 16;12:596428. doi: 10.3389/fpsyt.2021.596428. eCollection 2021.
7
Cardiac involvement in the long-term implications of COVID-19.COVID-19 对心脏的长期影响。
Nat Rev Cardiol. 2022 May;19(5):332-341. doi: 10.1038/s41569-021-00631-3. Epub 2021 Oct 22.
8
Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.抗病毒肽对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）活性的有力证据。
Viruses. 2021 May 14;13(5):912. doi: 10.3390/v13050912.
9
Lethal Arrhythmia () in COVID-19: An Event Synergistically Induced by Viral Associated Cardiac Injury, Hyperinflammatory Response, and Treatment Drug?新型冠状病毒肺炎中的致死性心律失常：病毒相关心脏损伤、过度炎症反应及治疗药物协同诱发的事件？
Clin Med Insights Case Rep. 2020 Dec 14;13:1179547620972397. doi: 10.1177/1179547620972397. eCollection 2020.
10
Dissecting the interaction between COVID-19 and diabetes mellitus.剖析 COVID-19 与糖尿病之间的相互作用。
J Diabetes Investig. 2020 Sep;11(5):1104-1114. doi: 10.1111/jdi.13326. Epub 2020 Aug 5.
本文引用的文献
1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
2
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).急件：针对新型冠状病毒病（COVID-19）可能的药物治疗的 QTc 延长和致扭转型心动过速的潜在风险的应对和规避指导建议。
Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024. Epub 2020 Apr 7.
3
Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin.使用动态遥测监测仪对接受羟氯喹和/或阿奇霉素治疗的COVID-19住院患者进行监测
J Am Coll Cardiol. 2020 Jun 16;75(23):2992-2993. doi: 10.1016/j.jacc.2020.04.032. Epub 2020 Apr 21.
4
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.高剂量与低剂量磷酸氯喹作为辅助治疗对住院的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者的影响：一项随机临床试验。
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
7
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
8
An interactive web-based dashboard to track COVID-19 in real time.一个基于网络的交互式仪表盘，用于实时追踪新冠病毒。
Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19.
9
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
10
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.氯喹和羟氯喹相关的心脏并发症：文献系统综述。
Drug Saf. 2018 Oct;41(10):919-931. doi: 10.1007/s40264-018-0689-4.
Zotero 插件